Table 2.
Characteristics of included studies.
| References | DSM-IV diagnosis | Treatment duration in weeks | Dose (mg) | Sample size | Age mean (SD) | Male (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | ||||||||||
| Varenicline | Placebo | Varenicline | Placebo | Varenicline | Placebo | Varenicline | Placebo | ||||
| Williams et al. (33) | SCZ/SCA | 12 | 0.5 × 3days, 1 × 4days, 2/day thereafter | 84 | 43 | 61 | 37 | 40.2 (11.9) | 43 (10.2) | 77.4 | 76.7 |
| Jeon et al. (43) | SCZ | 8 | 0.5 × 3days, 1 × 4days, 2/day thereafter | 30 | 30 | 23 | 22 | 41.1 (8.9) | 41.5 (8.8) | 86.7 | 96.7 |
| Hong et al. (46) | SCZ/SCA | 8 | 0.5 × 1week, 1 × 7week | 20 | 23 | 19 | 21 | 43 (11) | 41.5 (11.4) | 65 | 60.9 |
| Weiner et al. (19) | SCZ/SCA | 12 | 1/day | 4 | 5 | 4 | 4 | ND | ND | ND | ND |
SD, standard deviation; SCZ, schizophrenia; SCA, schizoaffective; d, days.